Related Experiment Video
Updated: Mar 25, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Patient-derived xenografts as tools in pharmaceutical development
E Izumchenko1, J Meir1, A Bedi1
1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract:
Successful drug development in oncology is grossly suboptimal, manifested by the very low percentage of new agents being developed that ultimately succeed in clinical approval. This poor success is in part due to the inability of standard cell-line xenograft models to accurately predict clinical success and to tailor chemotherapy specifically to a group of patients more likely to benefit from the therapy. Patient-derived xenografts (PDXs) maintain the histopathological architecture and molecular features of human tumors, and offer a potential solution to maximize drug development success and ultimately generate better outcomes for patients. Although imperfect in mimicking all aspects of human cancer, PDXs are a more predictable platform for preclinical evaluation of treatment effect and in selected cases can guide therapeutic decision making in the clinic. This article summarizes the current status of PDX models, challenges associated with modeling human cancer, and various approaches that have been applied to overcome these challenges and improve the clinical relevance of PDX cancer models.
Insights
Patient-derived xenografts (PDXs) improve oncology drug development by better predicting clinical success than traditional models. These models maintain tumor features, aiding treatment decisions and enhancing patient outcomes.
Area of Science:
- Oncology
- Translational Research
- Preclinical Drug Development
Background:
- Oncology drug development has a low success rate, partly due to inaccurate preclinical models.
- Standard cell-line xenografts fail to predict clinical efficacy and patient response.
- This necessitates more predictive models for successful cancer drug discovery.
Purpose of the Study:
- To review the current status and clinical relevance of patient-derived xenografts (PDXs) in oncology.
- To discuss challenges in modeling human cancer using PDXs.
- To explore approaches for improving the predictive power of PDX models.
Main Methods:
- Review of current literature on patient-derived xenografts (PDXs) in cancer research.
- Analysis of the advantages and limitations of PDXs compared to traditional models.
- Summary of strategies to enhance the clinical relevance of PDX models.
Main Results:
- PDXs retain human tumor histopathology and molecular characteristics.
- PDXs offer a more accurate preclinical platform for evaluating treatment efficacy.
- PDXs show potential in guiding clinical therapeutic decisions.
Conclusions:
- PDX models represent a significant advancement over standard xenografts for oncology drug development.
- Despite limitations, PDXs enhance the predictability of preclinical drug evaluation.
- Further optimization of PDX models is crucial for improving patient outcomes in cancer therapy.
More Related Videos
04:49Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research
Published on: May 5, 2021
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020